Current status and progress of the development of prostate cancer vaccines

At present, common treatments of prostate cancer mainly include surgery, radiotherapy, chemotherapy and hormone therapy. However, patients have high recurrence rate after treatment, and are prone to castration-resistant prostate cancer. Tumor vaccine is based on tumor specific antigen (TSA) and tumo...

Full description

Saved in:
Bibliographic Details
Published inJournal of Cancer Vol. 14; no. 5; pp. 835 - 842
Main Authors Wang, Jie, Zhou, Kaichen, Zhu, Huihuang, Wei, Fukun, Ma, Sai, Kan, Yi, Li, Bingheng, Mao, Lijun
Format Journal Article
LanguageEnglish
Published Australia Ivyspring International Publisher 01.01.2023
Subjects
Review
prostate cancer
tumor specific antigen
cancer vaccine
tumor associated antigen
Online AccessGet full text

Cover

More Information
Summary:At present, common treatments of prostate cancer mainly include surgery, radiotherapy, chemotherapy and hormone therapy. However, patients have high recurrence rate after treatment, and are prone to castration-resistant prostate cancer. Tumor vaccine is based on tumor specific antigen (TSA) and tumor associated antigen (TAA) to activate specific immune response of the body to cancer cells. With continuous maturity of tumor vaccine technology, different forms of prostate cancer vaccines have been developed, such as cellular vaccines, extracellular-based anti-tumor vaccines, polypeptide vaccines, and nucleic acid vaccines. In this review, we summarize current status and progress in the development of prostate cancer vaccines.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Competing Interests: The authors have declared that no competing interest exists.
Contributed equally
ISSN:1837-9664
1837-9664
DOI:10.7150/jca.80803